Muscle health in the modern era of incretin‐based therapies
European Journal of Clinical Investigation · 2026-01 · 56 (1)
DOI: 10.1111/eci.70155 ↗At a glance
Übersichtsarbeit in European Journal of Clinical Investigation, published online on 2025-12-02. Written by Giuseppe De Girolamo and 5 co-authors. Institution: Internal Medicine and Liver Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy. Major MEDLINE topics: Incretins, Muscle, Skeletal, Obesity, Weight Loss. Cited 13 times so far (Crossref); 46 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Background
Intentional weight loss improves obesity‐related outcomes but reduces lean body mass, raising concern about skeletal muscle mass, function and long‐term health. GLP‐1 receptor agonists (GLP‐1RAs) produce clinically meaningful weight loss primarily by lowering energy intake and slowing gastric emptying, with additional benefits on insulin sensitivity and inflammation.
Objective
To clarify GLP‐1RAs' effects on skeletal muscle tissue, body composition and physical function by reviewing preclinical and clinical evidence.
Findings
Across randomized and controlled studies, GLP‐1RAs reduce fat mass more than lean body mass. Functional measures appear preserved. Preclinical and early clinical data suggest improvements in muscle quality (microvascular recruitment, mitochondrial efficiency, reduced intramuscular fat) rather than hypertrophy.
Conclusions
GLP‐1RA‐induced weight loss is largely fat mass with modest absolute lean body mass decline and no consistent deterioration in strength or function. Progressive resistance training, adequate/high‐quality protein and periodic monitoring of body composition and performance should accompany therapy, especially in higher‐risk patients.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Internal Medicine and Liver Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
- Center for Human Nutrition, Washington University School of Medicine, St. Louis, Missouri, USA.
ORCID profiles: Giuseppe De Girolamo, Moris Sangineto
Cite
APA
De Girolamo, G., Sangineto, M., Di Gioia, G., Bianco, R., Ciarnelli, M., & Serviddio, G. (2026). Muscle health in the modern era of incretin‐based therapies. European Journal of Clinical Investigation, 56(1). https://doi.org/10.1111/eci.70155
Vancouver
De Girolamo G, Sangineto M, Di Gioia G, Bianco R, Ciarnelli M, Serviddio G. Muscle health in the modern era of incretin‐based therapies. European Journal of Clinical Investigation. 2026;56(1). doi:10.1111/eci.70155
BibTeX
@article{DeGirolamo2026,
author = {De Girolamo, Giuseppe and Sangineto, Moris and Di Gioia, Giuseppe and Bianco, Rossella and Ciarnelli, Martina and Serviddio, Gaetano},
title = {Muscle health in the modern era of incretin‐based therapies},
journal = {European Journal of Clinical Investigation},
year = {2026},
volume = {56},
number = {1},
doi = {10.1111/eci.70155}
}
EUVIMED